A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical...

Area of Science:

• Endocrinology
• Metabolic Disorders
• Cardiovascular Health

Background:

• Subclinical hypothyroidism (SCH) is prevalent and linked to dyslipidemia.
• Treatment of mild SCH with L-thyroxine for lipid improvement is debated.
• The benefit of L-thyroxine in mild SCH across different patient subgroups is unclear.

Purpose of the Study:

• To evaluate the efficacy of L-thyroxine replacement therapy on lipid profiles in patients with mild SCH.
• To determine if L-thyroxine treatment benefits mild SCH patients irrespective of baseline thyrotropin or lipid levels.

Main Methods:

• An open-label randomized controlled trial involving 378 mild SCH patients.
• Participants were randomized to receive L-thyroxine therapy or no treatment.
• The primary outcome measured was the change in serum total cholesterol (TC) concentration over 15 months.

Main Results:

• L-thyroxine treatment led to a significant reduction in total cholesterol (TC) compared to no treatment (-0.41 mmol/L vs. -0.17 mmol/L, p=0.012).
• Low-density lipoprotein cholesterol levels also showed a similar beneficial trend with L-thyroxine.
• Benefits on TC reduction were consistent across all baseline thyrotropin levels and independent of baseline TC levels.

Conclusions:

• L-thyroxine treatment is beneficial for improving lipid profiles in mild SCH patients.
• The positive effects of L-thyroxine on lipid profiles are evident regardless of initial thyrotropin or total cholesterol concentrations.
• These findings support L-thyroxine therapy for mild SCH to manage dyslipidemia.